Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1
Beatriz Tlatelpa Romero
 -- 1055 2023-01-03 18:22:22 |
2 format correct
Catherine Yang
 Meta information modification 1055 2023-01-04 02:00:28 |

Video Upload Options

We provide professional Video Production Services to translate complex research into visually appealing presentations. Would you like to try it?
No, upload directly Yes

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Tlatelpa-Romero, B.;  Cázares-Ordoñez, V.;  Oyarzábal, L.F.;  Vázquez-De-Lara, L.G. The Role of Pulmonary Surfactant Phospholipids in Interstitial Lung Diseases. Encyclopedia. Available online: https://encyclopedia.pub/entry/39692 (accessed on 02 December 2024).
Tlatelpa-Romero B,  Cázares-Ordoñez V,  Oyarzábal LF,  Vázquez-De-Lara LG. The Role of Pulmonary Surfactant Phospholipids in Interstitial Lung Diseases. Encyclopedia. Available at: https://encyclopedia.pub/entry/39692. Accessed December 02, 2024.
Tlatelpa-Romero, Beatriz, Verna Cázares-Ordoñez, Luis F. Oyarzábal, Luis G. Vázquez-De-Lara. "The Role of Pulmonary Surfactant Phospholipids in Interstitial Lung Diseases" Encyclopedia, https://encyclopedia.pub/entry/39692 (accessed December 02, 2024).
Tlatelpa-Romero, B.,  Cázares-Ordoñez, V.,  Oyarzábal, L.F., & Vázquez-De-Lara, L.G. (2023, January 03). The Role of Pulmonary Surfactant Phospholipids in Interstitial Lung Diseases. In Encyclopedia. https://encyclopedia.pub/entry/39692
Tlatelpa-Romero, Beatriz, et al. "The Role of Pulmonary Surfactant Phospholipids in Interstitial Lung Diseases." Encyclopedia. Web. 03 January, 2023.
The Role of Pulmonary Surfactant Phospholipids in Interstitial Lung Diseases
Edit
This entry is adapted from the peer-reviewed paper 10.3390/ijms24010326

Diffuse parenchymal lung diseases (DPLD) or Interstitial lung diseases (ILD) are a heterogeneous group of lung conditions with common characteristics that can progress to fibrosis. Within this group of pneumonias, idiopathic pulmonary fibrosis (IPF) is considered the most common. This disease has no known cause, is devastating and has no cure.

pulmonary surfactant phospholipids lung fibrosis

1. Introduction

Diffuse parenchymal lung diseases (DPLD) or Interstitial lung diseases (ILD) are a heterogeneous group of lung conditions with common characteristics that can progress to fibrosis. Within this group of pneumonias, idiopathic pulmonary fibrosis (IPF) is considered the most common. This disease has no known cause, is devastating and has no cure. Chronic lesion of alveolar type II (ATII) cells represents a key mechanism for the development of IPF. ATII cells are specialized in the biosynthesis and secretion of pulmonary surfactant (PS), a lipid-protein complex that reduces surface tension and minimizes breathing effort. Some differences in PS composition have been reported between patients with idiopathic pulmonary disease and healthy individuals, especially regarding some specific proteins in the PS; however, few reports have been conducted on the lipid components. This entry focuses on the mechanisms by which PLs could be involved in the development of the fibroproliferative response.

2. ILD of Know Cause: Occupational Exposure

1.1. Asbestosis

Asbestosis is pneumoconiosis caused by inhaling asbestos fibers, which elicit potent inflammatory responses in the respiratory tract [1]. It has been shown that asbestos can cause lipid peroxidation and trigger genomic alterations in pulmonary cells [2]. Furthermore, a decrease in phospholipase C (PLC) activity has been described, which directly impacts the biosynthesis of lipids like phosphatidylinositol, phosphatidylglycerol and phosphatidylserine, affecting macrophage activity and PS availability [3]. In asbestosis, alterations in the alveolar activity of CC-16 (specific proteins of clear cells), SP-A, and phospholipase A2 (PLA2) have been reported. [4]. The activity of PLA2 secreted in alveolar fluids and the effect of CC-16 on platelet growth factor-induced chemotaxis of human fibroblast [5]. SP-A is associated with lung diseases such as IPF and alveolar proteinosis [6], while increased PLA2 has been implicated in inflammatory lung disease pathologies such as respiratory distress syndrome, asthma and alveolar proteinosis [5]. A consequence of asbestos parenchymal damage is pulmonary fibrosis. The molecular mechanisms by which it could occur are primarily by the death of ATII cells mediated by mitochondrial and p53 death pathways resulting from the production of iron-derived reactive oxygen species (ROS) and DNA damage [7]. In the development of pulmonary fibrosis caused by asbestos, the death of ATII and the decrease in macrophage activity could be involved (Figure 1).
Figure 1. Asbestosis influences macrophage activity which is important for eliminating cellular debris, and acts on ATII cells by activating the mitochondrial and p53 death pathways. Asbestos catalyzes lipid peroxidation by decreasing PLC, which decreases phosphatidylinositol, phosphatidylglycerol, and phosphatidylserine synthesis. Another important event is the alteration of CC-16 with fibroblast chemotaxis activity, increased Sp-A and PLA2. Figure created in BioRender.com.

1.2. Silicosis

Occupational exposure to crystalline-free silica SiO2 dust causes silicon nodules and diffuse pulmonary fibrosis. Lung function is severely damaged by silicosis fibrosis, whose degree increases over time [8]. The alveoli of lungs affected by acute silicosis are lined by hypertrophic ATII, which produce proteinaceous materials, and PS is produced, resulting in protein-filled alveoli [9][10]. A high level of PS components in the lungs is a result of exposure to silica dust [11]. Disaturated phosphatidylcholine and SP-A levels increased in intracellular and extracellular PS compartments following silica exposure in rats [12]. A high concentration of silica reduces the number of alveolar macrophages, which are responsible for decreased DPPC liposomes during PS metabolism [13] (Figure 2).
Figure 2. Silica entering the alveolar space decreases the number of macrophages, induces hypertrophy of ATII cells and results in increased SP-A, DPPC and PLs, damaging alveolar homeostasis. Figure created in BioRender.com.

3. ILD of Know Cause: Related to Treatment

3.1. Radiation

Radiation therapy (also called radiotherapy) kills cancer cells and shrinks tumors by administering high doses of radiation. However, the use of radiotherapy can cause acute or chronic pneumonia [14]. The inflammatory process of acute pneumonia involves the formation of intra-alveolar and septal edema, as well as the formation of epithelial and endothelial desquamations. During acute pneumonia, ATII cells play a critical role in increasing microvascular permeability. This hypothesis is supported by the findings that ATII is the primary cellular response to lung injury. Then, a secondary response of ATII cell hyperplasia occurs as a result of the plasma protein overload on lymphatic and other drainage mechanisms. Consequently, an excess of PS results, causing a fall in compliance, abnormal gas exchange values, and even respiratory failure. As a result of the inflammatory process, chronic fibrosis can develop [15]. Other studies reveal that radiation causes apoptosis of epithelial cells, as well as a large amount of oxidative damage and release of fibrotic cytokines [16]. Oxidative damage affects lipid metabolism, increases inflammatory cytokines such as interferon-γ (INF-γ) and tumor necrosis factor-α (TNF-α) by macrophages [17]. Radiation increases glucose catabolism by increasing the levels of glycerophosphate as a lipid precursor [18], increases the expression of lipoproteins lipase and fatty acid binding protein (FABP4) and triacylglycerides, all resulting in lipid accumulation [19] (Figure 3).
Figure 3. Primary radiation increases microvascular permeability and plasma proteins that overwhelm the drainage mechanisms. This elicits a secondary response to hyperplasia of type II epithelial cells. In addition, there is an accumulation of pulmonary surfactant within the alveolus that triggers apoptosis of type II epithelial cells, oxidative damage and the release of fibrotic cytokines such as TNF-Υ and TNF-α. Primary radiation increases the catabolism of lipoprotein lipases due to increased glucose and glycerophosphate. This results in the release of fatty acids leading to decreased distensibility and respiratory failure. Figure created in BioRender.com.

3.2. Amiodarone

Amiodarone is a highly toxic antiarrhythmic drug that contains iodinated benzofuran, which causes fibrosis in the lungs [20]. Several studies have demonstrated that the accumulation of multilamellar bodies in the cytoplasm is the result of reduced degradation of PLs since amiodarone inhibits lysosomal phospholipases A1 and A2 [21][22]. Furthermore, amiodarone and the metabolite desethylamiodarone had a high capacity to bind to DPPC and prevent the reuptake of LBs [22]. Therefore, phospholipid accumulation and oxidative stress may contribute to pulmonary fibrosis through amiodarone exposure, so new therapies are aimed at modulating lipid homeostasis (Figure 4).
Figure 4. Amiodarone is metabolized to desethylamiodarone, which binds to DPPC, prevents it from being taken up by ATII cells and inhibits phospholipases and increases lipids in the alveolar space. Figure created in BioRender.com.

References

  1. Bhandari, J.; Thada, P.K.; Sedhai, Y.R. Asbestosis. In StatPearls; StatPearls Publishing: Treasure Island, FL, USA, 2021.
  2. La Maestra, S.; Micale, R.T.; Ferretti, M.; Izzotti, A.; Gaggero, L. Attenuation of Oxidative Stress and Chromosomal Aberrations in Cultured Macrophages and Pulmonary Cells Following Self-Sustained High Temperature Synthesis of Asbestos. Sci. Rep. 2020, 10, 8581.
  3. Jabbour, A.J.; Holian, A.; Scheule, R.K. Lung Lining Fluid Modification of Asbestos Bioactivity for the Alveolar Macrophage. Toxicol. Appl. Pharmacol. 1991, 110, 283–294.
  4. Lesur, O.; Bernard, A.M.; Bégin, R.O. Clara Cell Protein (CC-16) and Surfactant-Associated Protein A (SP-A) in Asbestos-Exposed Workers. Chest 1996, 109, 467–474.
  5. Gouveia, L.; Betsholtz, C.; Andrae, J. PDGF-A Signaling Is Required for Secondary Alveolar Septation and Controls Epithelial Proliferation in the Developing Lung. Development 2018, 145, dev161976.
  6. Carrington, J.M.; Hershberger, D.M. Pulmonary Alveolar Proteinosis. In StatPearls; StatPearls Publishing: Treasure Island, FL, USA, 2021.
  7. Liu, G.; Beri, R.; Mueller, A.; Kamp, D.W. Molecular Mechanisms of Asbestos-Induced Lung Epithelial Cell Apoptosis. Chem. -Biol. Interact. 2010, 188, 309–318.
  8. Krefft, S.; Wolff, J.; Rose, C. Silicosis: An Update and Guide for Clinicians. Clin. Chest Med. 2020, 41, 709–722.
  9. Greenberg, M.I.; Waksman, J.; Curtis, J. Silicosis: A Review. Dis. Mon. 2007, 53, 394–416.
  10. Hoffmann, E.O.; Lamberty, J.; Pizzolato, P.; Coover, J. The ultrastructure of acute silicosis. Arch. Pathol. 1973, 96, 104–107.
  11. Liu, X.; Wei, W.; Liu, Z.; Song, E.; Lou, J.; Feng, L.; Huang, R.; Chen, C.; Ke, P.C.; Song, Y. Serum Apolipoprotein A-I Depletion Is Causative to Silica Nanoparticles–Induced Cardiovascular Damage. Proc. Natl. Acad. Sci. USA 2021, 118, e2108131118.
  12. Miller, B.E.; Bakewell, W.E.; Katyal, S.L.; Singh, G.; Hook, G.E.R. Induction of Surfactant Protein (SP-A) Biosynthesis and SP-A MRNA in Activated Type II Cells during Acute Silicosis in Rats. Am. J. Respir. Cell Mol. Biol. 1990, 3, 217–226.
  13. Lesur, O.; Bouhadiba, T.; Melloni, B.; Cantin, A.; Whitsett, J.A.; Bégin, R. Alterations of Surfactant Lipid Turnover in Silicosis: Evidence of a Role for Surfactant-Associated Protein A (SP-A). Int. J. Exp. Pathol. 1995, 76, 287–298.
  14. De Ruysscher, D.; Niedermann, G.; Burnet, N.G.; Siva, S.; Lee, A.W.M.; Hegi-Johnson, F. Radiotherapy Toxicity. Nat. Rev. Dis. Primers 2019, 5, 13.
  15. Zanoni, M.; Cortesi, M.; Zamagni, A.; Tesei, A. The Role of Mesenchymal Stem Cells in Radiation-Induced Lung Fibrosis. Int. J. Mol. Sci. 2019, 20, 3876.
  16. Ubags, N.D.J.; Marsland, B.J. Mechanistic Insight into the Function of the Microbiome in Lung Diseases. Eur. Respir. J. 2017, 50, 1602467.
  17. Summer, R.; Mora, A.L. Lipid Metabolism: A New Player in the Conundrum of Lung Fibrosis. Am. J. Respir. Cell Mol. Biol. 2019, 61, 669–670.
  18. Ikeda, K.; Clark, J.C.; Shaw-White, J.R.; Stahlman, M.T.; Boutell, C.J.; Whitsett, J.A. Gene Structure and Expression of Human Thyroid Transcription Factor-1 in Respiratory Epithelial Cells. J. Biol. Chem. 1995, 270, 8108–8114.
  19. Gao, F.; Liu, C.; Guo, J.; Sun, W.; Xian, L.; Bai, D.; Liu, H.; Cheng, Y.; Li, B.; Cui, J.; et al. Radiation-Driven Lipid Accumulation and Dendritic Cell Dysfunction in Cancer. Sci. Rep. 2015, 5, 9613.
  20. Hamilton, D.; Nandkeolyar, S.; Lan, H.; Desai, P.; Evans, J.; Hauschild, C.; Choksi, D.; Abudayyeh, I.; Contractor, T.; Hilliard, A. Amiodarone: A Comprehensive Guide for Clinicians. Am. J. Cardiovasc. Drugs 2020, 20, 549–558.
  21. Baritussio, A.; Marzini, S.; Agostini, M.; Alberti, A.; Cimenti, C.; Bruttomesso, D.; Manzato, E.; Quaglino, D.; Pettenazzo, A. Amiodarone Inhibits Lung Degradation of SP-A and Perturbs the Distribution of Lysosomal Enzymes. Am. J. Physiol. Lung Cell. Mol. Physiol. 2001, 281, L1189–L1199.
  22. Kanagaki, S.; Suezawa, T.; Moriguchi, K.; Nakao, K.; Toyomoto, M.; Yamamoto, Y.; Murakami, K.; Hagiwara, M.; Gotoh, S. Hydroxypropyl Cyclodextrin Improves Amiodarone-Induced Aberrant Lipid Homeostasis of Alveolar Cells. Am. J. Respir. Cell Mol. Biol. 2021, 64, 504–514.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Medicine, Research & Experimental
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Beatriz Tlatelpa-Romero
,
Verna Cázares-Ordoñez
,
Luis F. Oyarzábal
,
Luis G. Vázquez-de-Lara
View Times: 774
Entry Collection: Biopharmaceuticals Technology
Revisions: 2 times (View History)
Update Date: 04 Jan 2023
Table of Contents
    1000/1000
    Hot Most Recent
    ScholarVision Creations
    Feedback